Condition Directory

Colorectal Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Colorectal Cancer. Browse Colorectal Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 5, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

157

Shown on this page

Current sort

How Colorectal Cancer studies are organized in the registry

Records may be registered under “colorectal,” “colon,” or “rectal” cancer — the three terms overlap but are not interchangeable in search, so check more than one if your interest spans them. Molecular labels (MSI-high, KRAS, BRAF) and the abbreviation mCRC for metastatic disease appear frequently in titles.

Terms that often appear in related listings

colon cancer rectal cancer MSI-high mCRC

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 157 matching trials for Colorectal Cancer.

Live ClinicalTrials.gov results.

Active filters: "mCRC" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Neoplasms
Interventions: GSK5764227, Bevacizumab, Fluorouracil, leucovorin, Enzalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Reunion, Florida • New Hyde Park, New York • Philadelphia, Pennsylvania + 2 more

Conditions: Colorectal Neoplasms, Gastrointestinal Neoplasms
Interventions: JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: Neonc Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more

Conditions: Metastatic Colorectal Cancer
Interventions: Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 24
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 20 more

Conditions: Untreated, Unresectable, or Metastatic Colorectal Cancer
Interventions: Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 46
States / cities: Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 40 more

Conditions: Metastatic Colorectal Cancer
Interventions: CA102N, TAS-102, Bevacizumab; Drug · Biological
Lead sponsor: Holy Stone Healthcare Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Metastatic Colorectal Cancer
Interventions: Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx; Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more

Conditions: Cancer
Interventions: TTX-080, pembrolizumab, cetuximab, FOLFIRI; Drug
Lead sponsor: Tizona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more

Conditions: Metastatic Colorectal Cancer (mCRC)
Interventions: 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Metastatic Colorectal Cancer
Interventions: Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Lone Tree, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 16 more

Conditions: Metastatic Colorectal Cancer (CRC)
Interventions: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 102
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 85 more

Conditions: NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Interventions: Pixatimod, Nivolumab, Cyclophosphamide (low dose); Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

About this Colorectal Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Colorectal Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Colorectal Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Colorectal Cancer clinical trials

How Colorectal Cancer studies are organized in the registry

Filter and sort this condition

Live official records

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

About this Colorectal Cancer clinical trials directory page